[go: up one dir, main page]

NO955288L - Skvalen-syntetase inhibitorer - Google Patents

Skvalen-syntetase inhibitorer

Info

Publication number
NO955288L
NO955288L NO955288A NO955288A NO955288L NO 955288 L NO955288 L NO 955288L NO 955288 A NO955288 A NO 955288A NO 955288 A NO955288 A NO 955288A NO 955288 L NO955288 L NO 955288L
Authority
NO
Norway
Prior art keywords
synthetase inhibitors
squalene synthetase
agents
squalene
inhibitors
Prior art date
Application number
NO955288A
Other languages
English (en)
Other versions
NO955288D0 (no
Inventor
Ernest S Hamanaka
Joel M Hawkins
Cheryl M Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO955288D0 publication Critical patent/NO955288D0/no
Publication of NO955288L publication Critical patent/NO955288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår visse benzoksazepinoner og benzotiazepinoner som er nyttige som hypokolesterolemiske midler og antiaterosklerose-midler.
NO955288A 1994-12-23 1995-12-22 Skvalen-syntetase inhibitorer NO955288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23
PCT/IB1995/000424 WO1996020184A1 (en) 1994-12-23 1995-06-02 Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors

Publications (2)

Publication Number Publication Date
NO955288D0 NO955288D0 (no) 1995-12-22
NO955288L true NO955288L (no) 1996-06-24

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955288A NO955288L (no) 1994-12-23 1995-12-22 Skvalen-syntetase inhibitorer

Country Status (26)

Country Link
US (1) US5770594A (no)
JP (1) JPH10500702A (no)
KR (1) KR960022510A (no)
CN (1) CN1133287A (no)
AU (1) AU4067795A (no)
BG (1) BG100248A (no)
BR (1) BR9505995A (no)
CA (1) CA2207772A1 (no)
CZ (1) CZ344795A3 (no)
FI (1) FI972696A7 (no)
GT (1) GT199500058A (no)
HU (1) HUT74672A (no)
IL (1) IL116399A0 (no)
IS (1) IS4312A (no)
LV (1) LV11325B (no)
MA (1) MA23746A1 (no)
MX (1) MX9704683A (no)
NO (1) NO955288L (no)
OA (1) OA10204A (no)
PE (1) PE60096A1 (no)
PL (1) PL311997A1 (no)
SI (1) SI9500393A (no)
SK (1) SK158795A3 (no)
TN (1) TNSN95133A1 (no)
TR (1) TR199501644A2 (no)
WO (1) WO1996020184A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
WO2008121602A1 (en) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235474T1 (de) * 1992-04-20 2003-04-15 Takeda Chemical Industries Ltd 4,1-benzoxazepinderivate als squalen-synthetase inhibitoren und ihre verwendung zur behandlung von hypercholesterämie und als fungizide
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor

Also Published As

Publication number Publication date
HUT74672A (en) 1997-01-28
NO955288D0 (no) 1995-12-22
KR960022510A (ko) 1996-07-18
FI972696A0 (fi) 1997-06-23
WO1996020184A1 (en) 1996-07-04
TNSN95133A1 (fr) 1996-02-06
OA10204A (en) 1996-12-18
AU4067795A (en) 1996-07-04
CN1133287A (zh) 1996-10-16
BG100248A (bg) 1996-07-31
MA23746A1 (fr) 1996-07-01
PL311997A1 (en) 1996-06-24
FI972696L (fi) 1997-06-23
JPH10500702A (ja) 1998-01-20
CZ344795A3 (en) 1996-09-11
HU9503783D0 (en) 1996-04-29
TR199501644A2 (tr) 1996-11-21
IS4312A (is) 1996-06-24
MX9704683A (es) 1997-09-30
LV11325A (lv) 1996-06-20
LV11325B (en) 1997-02-20
US5770594A (en) 1998-06-23
FI972696A7 (fi) 1997-06-23
IL116399A0 (en) 1996-03-31
SI9500393A (en) 1997-04-30
GT199500058A (es) 1997-06-05
CA2207772A1 (en) 1996-07-04
SK158795A3 (en) 1997-01-08
BR9505995A (pt) 1997-12-23
PE60096A1 (es) 1996-12-28

Similar Documents

Publication Publication Date Title
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
MY113489A (en) Reversible protease inhibitors
DE69424517D1 (de) Gaserzeugende Zusammensetzungen
DK0944590T3 (da) Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer
YU15299A (sh) Farmaceutski sastavi
ATE225772T1 (de) Thrombin-inhibitoren
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
DK0515544T3 (da) Steroidsulfataseinhibitorer
FI956119L (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
ES2182906T3 (es) Grapa quirurgica helicoidal.
DE69402043D1 (de) Verfahrenshilfsmittel für gaserzeugende Zusammensetzungen
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
NO954768D0 (no) N-alkyltiopolyaminderivater som radiobeskyttende midler
NO944406L (no) Nye 7 e inhibitorer
NO955288L (no) Skvalen-syntetase inhibitorer
DE19581542T1 (de) Gaserzeugende Zusammensetzung
EP0858262A4 (en) THROMBIN INHIBITORS
NO954321D0 (no) 4-aryl-4-hydroksy-tetrahydropyraner og 3-aryl-3-hydroksy-tetrahydrofuraner som 5-lipoksygenase-inhibitorer
GB2324091A (en) Metalloproteinase inhibitors
NO981019D0 (no) Deodoriserende preparater inneholdende kationiske biopolymerer, aluminiumklorhydrat og esteraseinhibitorer
DK0977871T3 (da) Neurotrypsin
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung